DURAGESIC-25
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-25 is a transdermal extended-release film containing fentanyl, a potent opioid analgesic. It is indicated for chronic pain management in opioid-tolerant patients. The product delivers consistent systemic opioid exposure over an extended period via transdermal absorption.
LOE Approaching
Mature product nearing loss of exclusivity with moderate competitive pressure (30% competitive intensity); team scaling will likely shift toward generic defense and lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURAGESIC-25 offers limited growth opportunity given its approaching loss of exclusivity and zero linked job openings. Career value lies in managing mature product defense, generic conversion strategy, and potentially transitioning to pipeline products within the pain management portfolio.
Brand ManagerField Sales Representative
Worked on DURAGESIC-25 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.